Trusopt Special Precautions

DORZOLAMIDE HCl (TRUSOPT) has not been studied in patients with severe renal impairment (CrCl <30 mL/min). Because DORZOLAMIDE HCl (TRUSOPT) and its metabolite are excreted predominantly by the kidney, DORZOLAMIDE HCl (TRUSOPT) is not recommended in such patients.
The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. DORZOLAMIDE HCl (TRUSOPT) has not been studied in patients with acute angle-closure glaucoma.
DORZOLAMIDE HCl (TRUSOPT) has not been studied in patients with hepatic impairment and should therefore be used with caution in such patients.
DORZOLAMIDE HCl (TRUSOPT) is a sulfonamide and although administered topically, is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation.
In clinical studies, local ocular adverse effects, primarily conjunctivitis and lid reactions, were reported with chronic administration of DORZOLAMIDE HCl (TRUSOPT). Some of these reactions had the clinical appearance and course of an allergic-type reaction that resolved upon discontinuation of drug therapy. If such reactions are observed, discontinuation of treatment with DORZOLAMIDE HCl (TRUSOPT) should be considered.
There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and DORZOLAMIDE HCl (TRUSOPT). The concomitant administration of DORZOLAMIDE HCl (TRUSOPT) and oral carbonic anhydrase inhibitors has not been studied and is not recommended.
Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g., dorzolamide) after filtration procedures.
Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g., dorzolamide) after filtration procedures.
Ophthalmic Solution contains the preservative benzalkonium chloride, which may be absorbed by soft contact lenses. Therefore, DORZOLAMIDE HCl (TRUSOPT) should not be administered while wearing soft contact lenses. The contact lenses should be removed before application of the drops and not be reinserted earlier than 15 minutes after use.
Use in Children: Safety and effectiveness in children have not been established.